Valion Bio, Inc. Earnings Per Share (Diluted)
Valion Bio, Inc. (VBIO) reported Earnings Per Share (Diluted) of -$2.19 per share for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2025-08-14
- Valion Bio, Inc. earnings per share, diluted for the quarter ending 2025-06-30 was -$2.19.
- Valion Bio, Inc. earnings per share, diluted for the quarter ending 2025-03-31 was -$2.52.
- Valion Bio, Inc. earnings per share, diluted for the quarter ending 2024-12-31 was $0.14, a 90.56% decline year-over-year.
- Valion Bio, Inc. earnings per share, diluted for the quarter ending 2024-09-30 was -$0.23.
- Valion Bio, Inc. earnings per share, diluted for fiscal 2024 was -$19.68.
- Valion Bio, Inc. earnings per share, diluted for fiscal 2023 was -$176.80.
- Valion Bio, Inc. earnings per share, diluted for fiscal 2022 was -$104.32.
- Valion Bio, Inc. earnings per share, diluted for fiscal 2021 was -$2.43.
| Period end | Earnings Per Share, Diluted 1 month | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 3 month as first filed | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 6 month as first filed | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 9 month as first filed | Earnings Per Share, Diluted 12 month | Earnings Per Share, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | -$2.19 10-Q · filed 2025-08-14 | -$4.64 10-Q · filed 2025-08-14 | $1.62 derived: net income ÷ weighted average shares · filed 2026-08-14 | $8.82 derived: net income ÷ weighted average shares · filed 2026-08-14 | |||||
| 2025-03-31 | -$2.52 10-Q · filed 2025-05-15 | $0.60 derived: net income ÷ weighted average shares · filed 2026-08-14 | $3.52 derived: net income ÷ weighted average shares · filed 2026-08-14 | $6.45 derived: net income ÷ weighted average shares · filed 2026-08-14 | |||||
| 2024-12-31 | $0.14 derived: net income ÷ weighted average shares · filed 2026-03-30 | $1.34 derived: net income ÷ weighted average shares · filed 2026-03-30 | $3.04 derived: net income ÷ weighted average shares · filed 2026-03-30 | -$19.68 10-K · filed 2025-03-21 | |||||
| 2024-09-30 | -$0.23 10-Q · filed 2024-11-14 | -$0.84 derived: net income ÷ weighted average shares · filed 2025-11-14 | -$1.07 10-Q · filed 2024-11-14 | -$5.14 derived: net income ÷ weighted average shares · filed 2025-11-14 | |||||
| 2024-06-30 | -$5.37 10-Q · filed 2025-08-14 | -$0.32 10-Q · filed 2024-08-14 | -$17.05 10-Q · filed 2025-08-14 | -$1.00 10-Q · filed 2024-08-14 | $12.58 derived: net income ÷ weighted average shares · filed 2025-11-14 | $473684.21 derived: net income ÷ weighted average shares · filed 2025-11-14 | |||
| 2024-03-31 | -$17.15 10-Q · filed 2025-05-15 | -$1.01 10-Q · filed 2024-05-15 | $5.22 derived: net income ÷ weighted average shares · filed 2025-11-14 | $69.73 derived: net income ÷ weighted average shares · filed 2025-11-14 | -$500.16 derived: net income ÷ weighted average shares · filed 2025-11-14 | ||||
| 2023-12-31 | $1.48 derived: net income ÷ weighted average shares · filed 2025-03-21 | $24.84 derived: net income ÷ weighted average shares · filed 2025-03-21 | $721.37 derived: net income ÷ weighted average shares · filed 2025-03-21 | -$176.80 10-K · filed 2025-03-21 | -$10.40 10-K · filed 2024-03-25 | ||||
| 2023-09-30 | -$1.48 10-Q · filed 2024-11-14 | -$5.23 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$10.60 10-Q · filed 2024-11-14 | -$18.50 derived: net income ÷ weighted average shares · filed 2024-11-14 | |||||
| 2023-06-30 | -$7.16 10-Q · filed 2024-08-14 | -$0.07 10-Q · filed 2023-08-14 | -$17.01 10-Q · filed 2024-08-14 | -$0.17 10-Q · filed 2023-08-14 | -$32.75 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$52.50 derived: net income ÷ weighted average shares · filed 2024-11-14 | |||
| 2023-03-31 | -$10.52 10-Q · filed 2024-05-15 | -$0.11 10-Q · filed 2023-05-15 | -$29.31 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$52.82 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$3.98 derived: net income ÷ weighted average shares · filed 2024-11-14 | ||||
| 2022-12-31 | -$23.24 derived: net income ÷ weighted average shares · filed 2024-03-25 | -$49.94 derived: net income ÷ weighted average shares · filed 2024-03-25 | -$2.40 derived: net income ÷ weighted average shares · filed 2024-03-25 | -$104.32 10-K · filed 2024-03-25 | -$1.04 10-K · filed 2023-03-31 | ||||
| 2022-09-30 | -$27.00 10-Q · filed 2023-11-14 | -$0.27 10-Q · filed 2022-11-14 | -$1.15 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$81.00 10-Q · filed 2023-11-14 | -$0.81 10-Q · filed 2022-11-14 | -$1.77 derived: net income ÷ weighted average shares · filed 2023-11-14 | |||
| 2022-06-30 | -$0.32 10-Q · filed 2023-08-14 | -$0.55 10-Q · filed 2023-08-14 | -$1.04 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$1.58 derived: net income ÷ weighted average shares · filed 2023-11-14 | |||||
| 2022-03-31 | -$0.23 10-Q · filed 2023-05-15 | -$0.73 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$1.31 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$1.76 derived: net income ÷ weighted average shares · filed 2023-11-14 | |||||
| 2022-01-31 | -$0.23 10-Q · filed 2022-05-16 | ||||||||
| 2021-12-31 | -$0.56 derived: net income ÷ weighted average shares · filed 2023-03-31 | -$1.31 derived: net income ÷ weighted average shares · filed 2023-03-31 | -$1.84 derived: net income ÷ weighted average shares · filed 2023-03-31 | -$2.43 10-K · filed 2023-03-31 | |||||
| 2021-09-30 | -$0.90 10-Q · filed 2022-11-14 | -$1.38 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$1.96 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | -$0.46 10-Q · filed 2022-08-15 | -$1.04 10-Q · filed 2022-08-15 | |||||||
| 2021-03-31 | -$0.58 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |